Lyme disease: Point/counterpoint

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 2, 2005, Pages 155-165

  Stricker, Raphael B ^a   Lautin, Andrew ^b   Burrascano, Joseph J ^c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c East End Medical Associates   (United States)

Author keywords

Anaplasma; Babesia; Bartonella; Borrelia; Coinfections; Ehrlichia; Lyme disease

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ATOVAQUONE; AZITHROMYCIN; BENZATHINE PENICILLIN; CEFDINIR; CEFIXIME; CEFOTAXIME; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CILASTATIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; EVERNIMICIN; HYDROXYCHLOROQUINE; IMIPENEM; KETOLIDE; LEVOFLOXACIN; LYME DISEASE VACCINE; LYMETRIX; MACROLIDE; MEFLOQUINE; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; NITROIMIDAZOLE; OXYGEN; PLANT EXTRACT; QUININE; RIFAMPICIN; S RIBOSYLHOMOCYSTEINASE; SALIVA PROTEIN; SULTAMICILLIN; TETRACYCLINE; TINIDAZOLE; TRIMETHOPRIM;

ANAPLASMA; ARTEMISIA; AWARENESS; BABESIA; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BARTONELLA; BLOOD BRAIN BARRIER; BORRELIA BURGDORFERI; CELL INVASION; CEREBROSPINAL FLUID ANALYSIS; CHRONIC DISEASE; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY CARE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DNA DETERMINATION; DRUG EFFICACY; EHRLICHIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; ERYTHEMA CHRONICUM MIGRANS; FIBROMYALGIA; GENDER; GENE EXPRESSION; GENETIC ANALYSIS; HEALTH CARE; HOST PARASITE INTERACTION; HUMAN; HYPERBARIC OXYGEN; IMMUNIZATION; IN VITRO STUDY; INCIDENCE; INFECTION RATE; INFECTION RISK; LONG TERM CARE; LYME DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVENTION AND CONTROL; PROTEIN TARGETING; REVIEW; SEROLOGY; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SYMPTOMATOLOGY; SYNOVIAL FLUID LEVEL; TICK BITE; WESTERN BLOTTING;

ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; DRUG DESIGN; HUMANS; LYME DISEASE; REPRODUCIBILITY OF RESULTS;

EID: 17844406115     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.2.155     Document Type: Review

References (123)

1. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. J. Am. Med. Assoc. 269, 1812-1816 (1993).
2. Burrascano JJ. The overdiagnosis of Lyme disease. J. Am. Med. Assoc. 270, 2682 (1993).
3. Knell RJ. Syphilis in renaissance Europe: rapid evolution of an introduced sexually transmitted disease? Proc. R. Soc. Lond. B. Biol. Sci. 271(Suppl. 4), S174-S176 (2004).
4. Perlman J. AIDS education: whose morality? Weekly Mail 28 March-4 April, 17 (1991).
5. Kolata G. Lyme disease is hard to catch and easy to halt, study finds. New York Times 13 June (2001).
6. Meek JI, Roberts CL, Smith EV, Cartter ML. Underreporting of Lyme disease by Connecticut physicians, 1992. J. Public Health Manage. Pract. 2, 61-65 (1996).
7. Lautin A, McNeil EL, Liegner KB, Stricker RB, Sigal LH. Lyme disease controversy: use and misuse of language. Ann. Intern. Med. 137, 775-777 (2002).
8. Bakken LK, Case KL, Callister SM, Bourdeau NJ, Schell RF. Peformance of 45 laboratories participating in a proficiency testing program for Lyme disease serology. J. Am. Med. Assoc. 268, 891-895 (1992).
9. Brown SL, Hanson SL, Langone JJ. Role of serology in the diagnosis of Lyme disease. J. Am. Med. Assoc. 282, 62-66 (1999).
10. Montgomery RR, Nathanson MH, Malawista SE. The fate of Borrelia burgdorferi, the agent for Lyme disease, in mouse macrophages. Destruction, survival, recovery. J. Immunol. 150, 909-915 (1993).
11. Bockenstedt LK, Mao J, Hodzic E, Barthold SW, Fish D. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. J. Infect. Dis. 186, 1430-1437 (2002).
12. Straubinger RK, Summers BA, Chang YF, Appel MJ. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J. Clin. Microbiol. 35, 111-116 (1997).
13. Straubinger RK. PCR-based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-day postinfection period. J. Clin. Microbiol. 38, 2191-2199 (2000).
14. Cadavid D, O'Neill T, Schaefer H, Pachner AR. Localization of Borrelia burgdorferi in the nervous system and other organs in a nonhuman primate model of Lyme disease. Lab. Invest. 80, 1043-1054 (2000).
15. Preac-Mursic V, Weber K, Pfister HW et al. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 17, 355-359 (1989).
16. Frey M, Jaulbac B, Piemont Y et al. Detection of Borrelia burgdorferi DNA in muscle of patients with chronic myalgia related to Lyme disease. Am. J. Med. 104, 591-594 (1998).
17. Oksi J, Marjamaki M, Nikoskelainen J et al. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann. Med. 31, 225-232 (1999).
18. Stricker RB, McNeil EL. Duration of antibiotic therapy for Lyme disease. Ann. Intern. Med. 140, W6 (2004).
19. Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 48, 534-5340 (2003).
20. Kalish RS, Wood JA, Golde W et al. Human T-lymphocyte response to Borrelia burgdorferi infection: no correlation between human leukocyte function antigen Type 1 peptide response and clinical status. J. Infect. Dis. 187, 102-108 (2003).
21. Stricker RB. Lyme disease: a potential polymicrobial infection. ASM News 69, 265 (2003).
22. Benach JL, Coleman JL, Habicht GS, MacDonald A, Grunwaldt E, Giron JA. Serological evidence for simultaneous occurrences of Lyme disease and babesiosis. J. Infect. Dis. 152, 473-477 (1985).
23. Marcus LC, Steere AC, Duray PH, Anderson AE, Mahoney EB. Fatal pancarditis in a patient with coexistent Lyme disease and babesiosis. Demonstration of spirochetes in the myocardium. Ann. Intern. Med. 103, 374-376(1985).
24. Nadelman RB, Horowitz HW, Hsieh TC et al. Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis. N. Engl. J. Med. 337, 27-30 (1997).
25. DeMartino SJ, Carlyon JA, Fikrig E. Coinfections with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis. N. Engl. J. Med. 345, 150-151 (2001).
26. Krause PJ, McKay K, Thompson CA et al. Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin. Infect. Dis. 34, 1184-1191 (2002).
27. Stricker RB, Harris NS, Yong DC, Winger EE. Clinical and seroepidemiologic characteristics of Babesia WA-1 coinfection in patients with Lyme disease in California. J. Invest. Med. 51(Suppl. 1), S145 (2003).
28. Eskow E, Rao RV, Mordechai E. Concurrent infection of the central nervous system by Borrelia burgdorferi and Bartonella henselae: evidence for a novel tick-borne disease complex. Arch. Neurol. 58, 1357-1363 (2001).
29. Holden K, Boothby JT, Anand S, Massung RF. Detection of Borrelia burgdorferi, Ehrlichia chafeensis, and Anaplasma phagocytophilum in ticks (Acari: Ixodidae) from a coastal region of California. J. Med. Entomol. 40, 534-539 (2003).
30. Burgess EC, Amundson TE, Davis JP, Kaslow RA, Edelman R. Experimental inoculation of Peromyscus spp. with Borrelia burgdorferi: evidence of contact transmission. Am. J. Trop. Med. Hyg. 35, 355-359 (1986).
31. Wright SD, Nielsen SW. Experimental infection of the white-footed mouse with Borrelia burgdorferi. Am. J. Vet. Res.. 51, 1980-1987 (1990).
32. Harvey WT, Salvato P. 'Lyme disease': ancient engine of an unrecognized borreliosis pandemic? Med. Hypoth. 60, 742-759 (2003).
33. Stricker RB, Moore DH, Winger EE. Clinical and immunologic evidence for transmission of Lyme disease through intimate human contact. J. Invest. Med. 52, S151 (2004).
34. Pavia CS. Current and novel therapies for Lyme disease. Expert Opin. Investig. Drugs 12(10), 1003-1016 (2003).
35. Hengge UR, Tannapfel A, Tyring SK, Erbel R, Arendt G, Ruzicka T. Lyme borreliosis. Lancet Infect. Dis. 3, 489-500 (2003).
36. Wormser GP, Nadelman RB, Dattwyler RJ et al. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin. Infect. Dis. 31 (Suppl. 1), 1-14 (2000).
37. The ILADS Working Group. Evidence-based guidelines for the management of Lyme disease. Expert Rev. Anti Infect. Ther. 2(1), S1-S13 (2004).
38. Johnson L, Stricker RB. Treatment of Lyme disease: a medicolegal assessment. Expert Rev. Anti Infect. Ther. 2(4), 533-557 (2004).
39. Stricker RB, Phillips SE. Lyme disease without erythema migrans: cause for concern? Am. J. Med. 115, 72 (2003).
40. Edlow JA. Erythema migrans. Med. Clin. North Am. 86,239-260 (2002).
41. Schoeler GB, Wikel SK. Modulation of host immunity by haematophagous arthropods. Ann. Trop. Med. Parasitol. 95, 755-771 (2001).
42. Hannier S, Liversidge J, Sternberg JM, Bowman AS. Ixodes ricinus tick salivary gland extract inhibits IL-10 secretion and CD69 expression by mitogen-stimulated murine splenocytes and induces hyporesponsiveness in B-lymphocytes. Parasite Immunol. 25, 27-37 (2003).
43. Rhea M, Erisson S, Clements M, Bergstrom S, Normark SJ. The basis of persistent bacterial infections. Trends Microbiol. 11, 80-86 (2003).
44. Liang FT, Jacobs MB, Bowers LC, Philipp MT. An immune evasion mechanism for spirocletal persistence in Lyme borreliosis. J. Exp. Med. 195, 415-422 (2002).
45. Guner ES. Complement evasion by the Lyme disease spirochete Borrelia burgdorferi grown in host-derived tissue cocultures: role of fibronectin in complement-resistance. Experientia 52, 364-372 (1996).
46. Ekerfelt C, Ernerudh J, Forsberg P et al. Lyme borreliosis in Sweden - diagnostic performance of five commercial borrelia serology kits using sera from well-defined patient groups. Acta Pathol. Microbiol. Immunol. Scandinavica 112, 74-78 (2004).
47. Boltri JM, Hash RB, Vogel RL. Patterns of Lyme disease diagnosis and treatment by family physicians in a southeastern state. J. Commun. Health 27, 395-402 (2002).
48. Ma B, Christen B, Leung D, Vigo-Pelfrey C. Serodiagnosis of Lyme borreliosis by Western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi. J. Clin. Microbiol. 30, 370-376 (1992).
49. Feder HM Jr, Gerber MA, Luger SW, Ryan RW. Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin. Infect. Dis. 15, 788-793 (1992).
50. Lane RS, Steinlein DB, Mun J. Human behaviors elevating exposure to Ixodes pacificus (Acari: Ixodidae) nymphs and their associated bacterial zoonotic agents in a hardwood forest. J. Med. Entomol. 41, 239-248 (2004).
51. Zore A, Ruzic-Sabljic E, Maraspin V et al. Sensitivity of culture and polymerase chain reaction for the etiologic diagnosis of erythema migrans. Wien Klin. Wochenschr. 114, 606-609 (2002).
52. Liveris D, Wang G, Girao G et al. Quantitative detection of Borrelia burgdorferi in 2-millimeter skin samples of Erythema migrans lesions: correlation of results with clinical and laboratory findings. J. Clin. Microbiol. 40, 1249-1253 (2002).
53. Hicks CB. Confronting the clinical uncertainty regarding syphilis. AIDS Clin. Care 15, 64-65 (2003).
54. Bruck DK, Talbot ML, Cluss RG, Boothby JT. Ultrastructural characterization of the stages of spheroplast preparation of Borrelia burgdorferi. J. Microbiol. Methods 23, 219-228 (1995).
55. Preac-Mursic V, Wanner G, Reinhardt S, Wilske B, Busch U, Marget W. Formation and cultivation of Borrelia burgdorferi spheroplast L-form variants. Infection 24, 218-226 (1996).
56. Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology 146(Pt 1), 119-127 (2000).
57. Brorson O, Brorson SH. A rapid method for generating cystic forms of Borrelia burgdorferi, and their reversal to mobile spirochetes. Acta Pathol. Microbiol. Immunol. Scandinavica 106, 1131-1141 (1998).
58. Brorson O, Brorson SH. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole. Acta Pathol. Microbiol. Immunol. Scandinavica 107, 566-576 (1999).
59. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on the morphology of Borrelia burgdorferi. Antimicrob. Agents Chemotber. 39, 1127-1133 (1995).
60. Aberer E, Koszik F, Silberer M. Why is chronic Lyme borreliosis chronic? Clin. Infect. Dis. 25(Suppl. 1), S64-S70 (1997).
61. Porcella SF, Schwan TG. Borrelia burgdorferi and Treponema pallidum: a comparison of functional genomics, environmental adaptations, and pathogenic mechanisms. J. Clin. Invest. 107, 651-656 (2001).
62. Casjens S, Palmer N, van Vugt R et al. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol. Microbiol. 35, 490-516 (2000).
63. Kraiczy P, Hellwage J, Skerka C et al. Complement resistance of Borrelia burgdorferi correlates with expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J. Biol. Chem. 279, 2421-2429 (2004).
64. Zhang H, Raji A, Theisen M, Hansen PR, Marconi RT. BdrF2 of Lyme disease spirochetes is coexpressed with a series of cytoplasmic proteins and is produced specifically during early infection. J. Bacteriol. 187, 175-184 (2005).
65. Liang FT, Brown EL, Wang T, Iozzo RV, Fikrig E. Protective niche for Borrelia burgdorferi to evade humoral immunity. Am. J. Pathol. 165, 977-985 (2004).
66. Liang FT, Yan J, Mbow ML et al. Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses. Infect. Immun. 72, 5759-5767 (2004).
67. Qiu WG, Schutzer SE, Bruno JF et al. Generic exchange and plasmid transfers in Borrelia burgdorferi sensu stricto revealed by three-way genome comparisons and multilocus sequence typing. Proc. Natl Acad. Sci. USA 101, 14150-14155 (2004).
68. Stewart PE, Hoff J, Fischer E, Krum JG, Rosa PA. Genome-wide transposon mutagenesis of Borrelia burgdorferi for identification of phenotypic mutants. Appl. Environ. Microbiol. 70, 5973-5979 (2004).
69. Grimm D, Eggers CH, Caimano MJ et al. Experimental assessment of the roles of linear plasmids lp25 and lp28-1 of Borrelia burgdorferi throughout the infectious cycle. Infect. Immun. 72, 5938-5946 (2004).
70. Cluss RG, Silverman DA, Stafford TR. Extracellular secretion of the Borrelia burgdorferi Oms28 porin and Bgp, a glycosaminoglycan binding protein. Infect. Immun. 72, 6279-6286 (2004).
71. Grab DJ, Perides G, Dumler JS et al. Borrelia burgdorferi host-derived proteases, and the blood-brain barrier. Infect. Immun. 73, 1014-1022 (2005).
72. Terekhova D, Sartakova ML, Wormser GP, Schwartz I, Cabello FC. Erythromycin resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother. 46, 3637-3640 (2002).
73. Ma Y, Sturrock A, Weis JJ. Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect. Immun. 59, 671-678 (1991).
74. Klempner MS, Noring R, Rogers RA. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. J. Infect. Dis. 167, l074-1081 (1993).
75. Girschick HJ, Huppertz HI, Russmann H, Krenn V, Karch H. Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol. Intl 16, 125-130 (1996).
76. Linder S, Heimerl C, Fingerle V, Aepfelbacher M, Wilske B. Coiling phagocytosis of Borrelia burgdorferi by primary human macrophages is controlled by CDC42Hs and Rac1 and involves recruitment of Wiskott-Aldrich syndrome protein and Arp2/3 complex. Infect. Immun. 69, 1739-1746 (2001).
77. Georgilis K, Peacocke M, Klempner MS. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro. J. Infect. Dis. 166, 440-444 (1992).
78. Brouqui P, Badiaga S, Raoult D. Eukaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin. Antimicrob. Agents Chemotber. 40, 1552-1554 (1996).
79. Embers ME, Ramamoorthy R, Philipp MT. Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease. Microbes Infect. 6, 312-318 (2004).
80. Chan J, Flynn J. The immunological aspects of latency in tuberculosis. Clin. Immunol. 110, 2-12 (2004).
81. Mukamolova GV, Turapov OA, Young DI, Kaprelyants AS, Kell DB, Young M. A family of autocrine growth factors in Mycobacterium tuberculosis. Mol. Microbiol. 46, 623-635 (2002).
82. Stevenson B, von Lackum K, Wattier RL, McAlister JD, Miller JC, Babb K. Quorum sensing by the Lyme disease spirochete. Microbes Infect. 5, 991-997 (2003).
83. Thomas V, Anguita J, Barthold SW, Fikrig E. Coinfection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis alters murine immune responses, pathogen burden, and severity of Lyme arthritis. Infect. Immun. 69, 3359-3371 (2001).
84. Zeidner NS, Dolan MC, Massung R, Piesman J, Fish D. Coinfection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis suppresses IL-2 and IFN gamma production and promotes an IL-4 response in C3H/HeJ mice. Parasite Immunol. 22, 581-588 (2000).
85. Moro MH, Zegarra-Moro OL, Bjornsson J et al. Increased arthritis severity in mice coinfected with Borrelia burgdorferi and Babesia microti. J. Infect. Dis. 186, 428-431 (2002).
86. Krause PJ, 6Telford SR 3rd, Spielman A et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. J. Am. Med. Assoc. 275, 1657-1660 (1996).
87. Oleson CV, Sivalingam JJ, O'Neill BJ, Staas WE. Transverse myelitis secondary to coexistent Lyme disease and babesiosis. J. Spinal Cord Med. 26, 168-171 (2003).
88. Krause PJ, Spielman A, Telford SR et al. Persistent parasitemia after acute babesiosis. N. Engl. J. Med. 339, 160-165 (1998).
89. Allzed DR. Babesiosis: persistence in the face of adversity. Trends Parasitol. 19, 51-55 (2003).
90. Harrus S, Waner T, Aizenberg I, Foley JE, Poland AM, Bark H. Amplification of ehrlichial DNA from dogs 34 months after infection with Ehrlichia canis. J. Clin. Microbiol. 36, 73-76 (1998).
91. Dumler JS, Bakken JS. Human granulocytic ehrlichiosis in Wisconsin and Minnesota: a frequent infection with the potential for persistence. J. Infect. Dis. 173, 1027-1030 (1996).
92. Chomel BB, Kasten RW, Sykes JE, Boulouis HJ, Breitschwerdt EB. Clinical impact of persistent Bartonella bacteremia in humans and animals. Ann. NY Acad. Sci. 990, 267-278 (2003).
93. Nadelman RB, Wormser GP. Single-dose doxycycline for die prevention of Lyme disease. N. Engl. J. Med. 345, 1349-1350 (2001).
94. Wormser GP, Ramanathan R, Nowakowski J et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 138, 697-704 (2003).
95. Stricker RB, Gaito A, Harris NS, Burrascano JJ. Treatment of early Lyme disease. Ann. Intern. Med. 140, 577 (2004).
96. Klempner MS, Hu LT, Evans J et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345, 85-92 (2001).
97. Bransfield B, Brand S, Sherr V. Treatment of patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345, 1424-1425 (2001).
98. Fallon BA. Laboratory findings in chronic Lyme disease and results of a controlled treatment study. Presented at the Annual Meeting of the Lyme Disease Association. Rye, NY, USA, 22 October 2004.
99. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid in Lyme arthritis. N. Engl. J. Med. 330, 229-234 (1994).
100. Nocion JJ, Bloom BJ, Rutledge BJ et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in patients with Lyme neuroborreliosis. J. Infect. Dis. 174, 623-627 (1996).
101. l Lawrence C, Lipton RB, Lowy FD, Coyle PK. Seronegative chronic relapsing neuroborreliosis. Eur. Neurol. 35, 113-117 (1995).
102. Fraser DD, Kong LI, Miller FW. Molecular detection of persistent Borrelia burgdorferi in a man with dermatomyositis. Clin. Exp. Rheumatol. 10, 387-390 (1992).
103. Burrascano JJ. Lyme disease. In: Conn's Current Therapy WB Saunders Company, PA, USA, 140-143 (1997).
104. Liegner KB, Kochevar J. Guidelines for the clinical diagnosis of Lyme disease. Ann. Intern. Med. 129, 422-423 (1998).
105. Hanson MS, Edelman R. Progress and controversy surrounding vaccines against Lyme disease. Expert Rev. Vaccines 2(5), 683-703 (2003).
106. Valenzuela JG. Exploring the messages of the salivary glands of Ixodes ricinus. Am. J. Trop. Med. Hyg. 66(3), 223-224 (2002).
107. Burke G, Wikel SK, Spielman A, Telford SR, McKay K, Krause PJ and the Tick-borne study group. Hypersensitivity to ticks and Lyme disease risk. Emerg. Infect. Dis. 11, 36-41 (2005).
108. Tsao JI, Wootton JT, Bunikis J, Luna MG, Fish D, Barbour AG. An ecological approach to preventing human infection: vaccinating wild-mouse reservoirs intervenes in the Lyme disease cycle. Proc. Natl Acad. Sci. USA 101, 18159-18164 (2004).
109. Stricker RB, Winger EE. Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. Immunol. Lett. 76, 43-48 (2001).
110. Stricker RB, Burrascano J, Winger EE. Longterm decrease in the CD57 lymphocyte subset in a patient with chronic Lyme disease. Ann. Agric. Environ. Med. 9, 111-113 (2002).
111. Stricker RB, Winger EE. Normalization of the CD57 natural killer cell subset associated with prolonged antibiotic therapy in patients with chronic Lyme disease. Clin. Immunol. 103, S117-S118 (2002).
112. Brorson O, Brorson SH. An in vitro study ofthe susceptibility of mobile and cystic forms of Borrelia burgdorferi to tinidazole. Intl Microbiol. 7, 139-142 (2004).
113. Hunfeld KP, Wichelhaus TA, Rodel R, Acker G, Brade V, Kraiczy P. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 48, 344-347 (2004).
114. Stricker RB, Thomas SL, Moore DH, Winger EE. Efficacy of clarithromycin/cefdinir combination therapy in patients with chronic Lyme disease. J. Invest. Med. 53, S156 (2005).
115. Widhe M, Grusell M, Ekerfelt C, Vrethem M, Forsberg P, Ernerudh J. Cytokines in Lyme borreliosis: lack of early TNF-α and TGF-β 1 responses are associated with chronic neuroborreliosis. Immunology 107, 46-55 (2002).
116. Widhe M, Jarefors S, Ekerfelt C et al. Borrelia specific IFN-γ and IL-4 secretion in blood and CSF during the course of human Lyme borreliosis: relation to clinical outcome. J. Infect. Dis. 189, 1881-1891 (2004).
117. Fallon RA, Das S, Plutchok JJ, Tager F, Liegner K, Van Heertum R. Functional brain imaging and neuropsychological testing in Lyme disease. Clin. Infect. Dis. 25(Suppl. 1), S57-S63 (1997).
118. Liegner KB, Duray P, Agricola M et al. Lyme disease and the clinical spectrum of antibiotic responsive chronic meningoencephalomyelitides. J. Spiro. Tick Dis. 4, 61-73 (1997).
119. Small PM, Fujiwara PI. Management of tuberculosis in the USA. N. Engl. J. Med. 345, 189-200 (2001).
120. Shaw IN, Natrajan MM, Rao GS, Jesudasan K, Christian M, Kavitha M. Long-term follow-up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of 2 years. Int. J. Lepr. Other Mycobact. Dis. 68, 405-409 (2000).
121. Goto M. Chemotherapy of leprosy: theoretical basis of new guideline in Japan. Nihon Hansenbyo Gakkai Zasshi 70, 151-155 (2001).
122. Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann. Intern. Med. 119, 482-486 (1993).
123. Rolain JM, Mallet MN, Raoult D. Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis. J. Infect. Dis. 188, 1322-1325 (2003).